We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

15 hedge funds and large institutions have $85.3M invested in Tonix Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

64% more capital invested

Capital invested by funds: $52M → $85.3M (+$33.3M)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

25% more funds holding

Funds holding: 12 → 15 (+3)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.3M
2
State Street
State Street
Massachusetts
+$5.88M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.94M
4
Norges Bank
Norges Bank
Norway
+$2.94M
5
Northern Trust
Northern Trust
Illinois
+$2.94M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.47M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.01M
3
Citadel Advisors
Citadel Advisors
Florida
-$776K
4
ECM
ExodusPoint Capital Management
New York
-$735K
5
Millennium Management
Millennium Management
New York
-$735K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
76
American International Group
New York
$203 – – –
Nisa Investment Advisors
77
Nisa Investment Advisors
Missouri
$46 – – –
Citadel Advisors
78
Citadel Advisors
Florida
– -$776K -1 Closed
HF
79
HRT Financial
New York
– -$445K -1 Closed
LP
80
LMR Partners
United Kingdom
– -$500K -1 Closed
Susquehanna International Group
81
Susquehanna International Group
Pennsylvania
– -$1.01M -1 Closed
Balyasny Asset Management
82
Balyasny Asset Management
Illinois
– -$45K – –
Bank of Montreal
83
Bank of Montreal
Ontario, Canada
– -$1K – –
Capstone Investment Advisors
84
Capstone Investment Advisors
New York
– -$73K – –
CM
85
Capula Management
Cayman Islands
– -$16K – –
Cerity Partners
86
Cerity Partners
New York
– -$20K – –
Creative Planning
87
Creative Planning
Kansas
– -$21K – –
CSS
88
Cubist Systematic Strategies
Connecticut
– -$27K – –
GC
89
Grimes & Company
Massachusetts
– -$26K – –
IAIM
90
International Assets Investment Management
Florida
– -$1K – –
JG
91
Jefferies Group
New York
– -$58.2K – –
NFG
92
Norris Financial Group
South Carolina
– -$23.7K – –
SSA
93
Schonfeld Strategic Advisors
New York
– -$17K – –
SFS
94
Sowell Financial Services
Arkansas
– -$17K – –
VFA
95
Valeo Financial Advisors
Indiana
– -$20K – –
VHAM
96
Van Hulzen Asset Management
California
– -$23K – –
1 2 3
4

TNXP Hedge Fund Activity: Q2 2021 in Review

15 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q2 2021, worth a combined $85.3M — up 64% from $52M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TNXP positions and 5 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $21.3M. The largest seller was Renaissance Technologies, cutting an estimated $1.47M.

  • 15 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q2 2021, up from 12 in Q1 2021.
  • Funds reported $85.3M of Tonix Pharmaceuticals stock for Q2 2021, up 64% quarter-over-quarter.
  • 8 funds opened new Tonix Pharmaceuticals positions in Q2 2021 and 5 closed out, a net change of +3 holders.
  • The largest Tonix Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $21.3M added.
  • The largest Tonix Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $1.47M sold.

Based on aggregated 13F filings for Q2 2021.